---
title: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39555826/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241119173555&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with tirzepatide led to a lower risk of a composite
  of death from cardiovascular causes or worsening heart failure than placebo and
  improved health status in patients with heart failure with preserved ejection fraction
  and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, ...